Dr. Reardon On Nivolumab/Ipilimumab In Glioblastoma

Dr. Reardon on Nivolumab/Ipilimumab in Glioblastoma

Dr. Reardon on the Immunogenicity of Glioblastoma

Dr. Reardon on Efficacy/Safety of Immunotherapy Combination in Glioblastoma

Dr. David Reardon on Immunotherapy and Rindopepimut in the Glioblastoma Treatment Paradigm

Targeted Oncology

ASCO22: Glioblastoma research by David Reardon, MD | Dana-Farber Cancer Institute

Dana-Farber Cancer Institute

Dr. Sampson on Nivolumab Monotherapy for Recurrent Glioblastoma

Dr. Reardon on the Need for a New Standard of Care in GBM

Dr. Reardon Discusses the Mechanism of Action of Rindopepimut for Recurrent Glioblastoma

Targeted Oncology

Dr. David Reardon on Treating Glioblastoma Patients With EGFRvIII-Mutations

Targeted Oncology

David Reardon on Caring for Patients With Glioblastoma

Dr. Sharpless on Managing Toxicities With Nivolumab/Ipilimumab in Melanoma

Dr. Atkinson on When to Use Nivolumab Monotherapy Versus Nivolumab/Ipilimumab Combination

Ipilimumab and Nivolumab for Newly Diagnosed Glioblastoma (GBM)

Dr. Reardon on Updated Data From the Phase II ReACT Trial

Dr. Schuchter Discusses Managing Ipilimumab's Side Effects

Dr. Reardon on a Phase 1/2 Trial Examining INO-5401 and INO-9012 in Glioblastoma

Dr. Reardon on Pembrolizumab and Bevacizumab for Glioblastoma

When Should I Ask About Immunotherapy Trials for Glioblastoma? Ask a Scientist

Cancer Research Institute

Nivolumab for Patients With MGMT Promoter Methylated Glioblastoma

Dr. Ernstoff Discusses Nivolumab and Ipilimumab in Advanced Melanoma